Serious health threat of mucormycosis during the ongoing COVID ‐19 pandemic: what dermatologists need to know in this regard

BACKGROUND: Recently, a surge of mucormycosis in patients affected with or recovered from SARS-Cov-2 has been noted, especially in developing countries such as India, Pakistan, and Iran. AIM: To focus on existing data about the important aspects of COVID-associated mucormycosis. METHODS: We searched on PubMed, Google Scholar, and Scopus in this regard, and all of the relevant papers published until August 28, 2021, for which we could access their full-texts, were included. RESULTS: We found some recommendations made by ophthalmologists, anesthesiologists, and ENT surgeons and tried to summarize them to provide a practical guide for dermatologists. CONCLUSION: Careful examination and clinical suspicion are the key factors for correct diagnosis especially in patients affected by or recently recovered from COVID. Implementing some preventive measures such as using a titrated dose of corticosteroids and encouraging patients to get vaccinated should be considered to tackling this serious issue.